• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Empagliflozin Targeting the Real-World Heart Failure Population.

作者信息

Rocha Bruno M L, Gomes Rita V, Cunha Gonçalo J L, Mendes Gonçalo, Morais Rui, Campos L, Araújo Inês, Fonseca Cândida

机构信息

Unidade de Insuficiência Cardíaca, Serviço de Medicina III, Hospital de São Francisco Xavier, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal.

Unidade de Insuficiência Cardíaca, Serviço de Medicina III, Hospital de São Francisco Xavier, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal; Serviço de Cardiologia, Hospital Vila Franca de Xira, Lisbon, Portugal.

出版信息

J Card Fail. 2019 Mar;25(3):218-219. doi: 10.1016/j.cardfail.2019.02.002. Epub 2019 Feb 10.

DOI:10.1016/j.cardfail.2019.02.002
PMID:30743044
Abstract
摘要

相似文献

1
Empagliflozin Targeting the Real-World Heart Failure Population.恩格列净针对现实世界中的心力衰竭人群。
J Card Fail. 2019 Mar;25(3):218-219. doi: 10.1016/j.cardfail.2019.02.002. Epub 2019 Feb 10.
2
Empagliflozin and Major Renal Outcomes in Heart Failure.恩格列净与心力衰竭的主要肾脏结局
N Engl J Med. 2021 Oct 14;385(16):1531-1533. doi: 10.1056/NEJMc2112411. Epub 2021 Aug 27.
3
Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.在 2 型糖尿病合并慢性心力衰竭患者中 SGLT2 抑制剂联合袢利尿剂的肾脏和心血管影响：RECEDE-CHF 试验。
Circulation. 2020 Nov 3;142(18):1713-1724. doi: 10.1161/CIRCULATIONAHA.120.048739. Epub 2020 Aug 29.
4
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
5
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).与其他降糖药物相比，起始使用钠-葡萄糖协同转运蛋白2抑制剂的患者发生心力衰竭和死亡的风险更低：CVD-REAL研究（钠-葡萄糖协同转运蛋白2抑制剂新使用者心血管结局的比较有效性）
Circulation. 2017 Jul 18;136(3):249-259. doi: 10.1161/CIRCULATIONAHA.117.029190. Epub 2017 May 18.
6
Are Two Gliflozins Different: A Prospective Multicenter Randomized Study to Assess Effect of Remogliflozin Compared With Empagliflozin on Biomarkers of Heart Failure in Indian Patients With Type 2 Diabetes Mellitus with Chronic Heart Failure (REMIT-HF Study).两种格列净类药物是否不同：一项前瞻性多中心随机研究，旨在评估瑞格列净与恩格列净对患有慢性心力衰竭的印度2型糖尿病患者心力衰竭生物标志物的影响（REMIT-HF研究）。
J Card Fail. 2025 Jan;31(1):158-162. doi: 10.1016/j.cardfail.2024.07.020. Epub 2024 Aug 14.
7
Real-Life Individual Comparison of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure and Diabetes Mellitus.心力衰竭合并糖尿病患者中钠-葡萄糖协同转运蛋白2抑制剂的真实个体比较
Am J Cardiovasc Drugs. 2025 Mar;25(2):277-286. doi: 10.1007/s40256-024-00698-6. Epub 2024 Nov 28.
8
Single dose of empagliflozin increases in vivo cardiac energy status in diabetic db/db mice.单剂量恩格列净可提高糖尿病db/db小鼠的体内心脏能量状态。
Cardiovasc Res. 2018 Dec 1;114(14):1843-1844. doi: 10.1093/cvr/cvy246.
9
Immediate and short-term outcomes of in-hospital canagliflozin initiation in acute heart failure: Results from the CANA-AHF randomized clinical trial.急性心力衰竭住院期间起始使用卡格列净的即刻和短期结局：CANA-AHF随机临床试验结果
Heart Lung. 2025 Jul-Aug;72:65-73. doi: 10.1016/j.hrtlng.2025.03.007. Epub 2025 Apr 3.
10
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.恩格列净对心力衰竭患者估算细胞外液量、估算血浆量和肾小球滤过率的影响（Empire HF Renal）：一项双盲、随机、安慰剂对照试验的预先指定亚研究。
Lancet Diabetes Endocrinol. 2021 Feb;9(2):106-116. doi: 10.1016/S2213-8587(20)30382-X. Epub 2020 Dec 22.

引用本文的文献

1
Empagliflozin in the treatment of heart failure.恩格列净治疗心力衰竭。
Future Cardiol. 2024 Apr 25;20(5-6):251-261. doi: 10.1080/14796678.2024.2360818. Epub 2024 Jun 12.
2
Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs.常规临床实践证据：EMPIRSE 为 CVOT 提供了新视角。
Cardiovasc Diabetol. 2019 Aug 31;18(1):115. doi: 10.1186/s12933-019-0920-3.